Navigation Links
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:7/20/2009

--- B (n=8) 50 mg/day -0.69 1 ------ ------------ ----- --- C (n=8) 75 mg/day -0.70 2 ------ ------------ ----- --- D (n=9) 100 mg/day -0.74 4 ------ ------------ ----- --- Control Placebo (n=8) +0.01 0 * Eight subjects were randomized to this cohort, two of whom were excluded from the viral load evaluation due to an error in dosing.

"We are pleased with the results of this study, which support the potential for IDX184 to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and tolerability, coupled with a low once-daily dose," said Douglas Mayers, M.D., chief medical officer of Idenix. "Now that we have successfully completed the proof-of-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the current standard-of-care, pegylated interferon and ribavirin, to determine the optimal IDX184 doses to advance into broader clinical trials."

In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean AST and ALT levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned to baseline 14 days post-treatment.

"We have made great progress in our HCV discovery and development programs this year," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "With the successful completion of the proof-of-concept study for IDX184 and plans to file investigational new drug applications in the coming
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  Lehigh Valley Health Network has announced the ... adding to its existing arsenal of five 5-foot-5 germ-killing ... within the network, LVHN is now deploying the largest ... superbugs and provide the best possible patient care available. ... TRU-D – the signature product of Memphis ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... Cardiovascular LLC, a leading provider of cardiovascular technologies, ... clearance and CE mark today at the 2011 ... Francisco  for its new CARDIOSAVE intra-aortic balloon pump ... in the United States in January 2012. ...
... Millar Instruments, Inc. (Houston, TX) and Telemetry ...  They expect to complete the transaction within the next ... world class organization to provide quality, innovative sensing and ... Instruments, pressure sensing technology is acknowledged as the gold ...
Cached Medicine Technology:MAQUET Cardiovascular Announces FDA 510(k) Clearance and CE Mark for the CARDIOSAVE™ Intra-Aortic Balloon Pump 2MAQUET Cardiovascular Announces FDA 510(k) Clearance and CE Mark for the CARDIOSAVE™ Intra-Aortic Balloon Pump 3Millar Instruments, Inc. and Telemetry Research Ltd Merge 2
(Date:5/21/2013)... Medical Ministry International announced today that ... by GreatNonprofits , the leading provider of user reviews ... a Top-Rated 2013 Nonprofit,” says Samuel Smith, MMI CEO. ... 3000 Volunteers and Staff serving in 22 countries around the ... those that have seen our work first hand and wanted ...
(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 Mecklenburg ... Charlotte will hold a free Community Wellness Fair to ... The fair will be held on Wednesday, May 22, ... University City YMCA (8100 Old Mallard Creek Road, Charlotte, ... American Heart Association and the Mecklenburg County Department ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... 2013 The In View series ... and cable channels across the country, announces it has ... channel. The producers of the series proudly bring audiences ... industry, the manufacturing industry, health-related companies, medical facilities and ... medical practitioners in all parts of the United States, ...
Breaking Medicine News(10 mins):Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2
... Tobacco-Free,Kids, WASHINGTON, Oct. 2 The following is ... Kids:, The Campaign for Tobacco-Free Kids applauds Tyra ... exposing the ugly truth that,smoking is not only dangerous ... week,s season premiere of "America,s Next Top Model",featured a ...
... Manchester scientists will discuss their research aimed at reducing ... at the National Cancer Research Institute conference in Birmingham ... patients receive radiotherapy as part of their cancer treatment ... causing side effects (toxicity) to the normal tissues and ...
... For the first time, data show a positive ... overall health at birth. Babies born to women with ... to be less likely to need intensive care than ... Inc. (NASDAQ:CBRX) announced today. The data are published in ...
... Angel Flight West (AFW),awarded The Distinguished Pilot award ... Awards on Saturday, September 29. Dr. Irish,completed 18 Angel ... AFW,pilot, he flies people in need whose non-emergency health ... facilities. Dr. Irish, like,all AFW volunteer pilots, donates the ...
... Does your October purchase really make a difference?, ... products to,benefit the breast cancer cause, Y-ME National Breast ... make meaningful,consumer choices to ensure that their money really ... consumers can take to become informed about,pink, promotions so ...
... HILL, N.C., Oct. 2 The U.S. hospital ... vying to get their,therapies on hospital formularies. Among ... time with key physicians and the list of ... companies are working their way into formularies via,specialized ...
Cached Medicine News:Health News:Tobacco-Free Kids Applauds Tyra Banks for Exposing the Ugly Truth About Smoking 2Health News:Cancer researchers seek safe reduction of radiotherapy 2Health News:Vaginal progesterone gel may improve infant outcomes and... 2Health News:Vaginal progesterone gel may improve infant outcomes and... 3Health News:Vaginal progesterone gel may improve infant outcomes and... 4Health News:Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2Health News:National Breast Cancer Awareness Month 2Health News:Equipping your Sales Force to Influence Hospital Formulary Decision-Makers 2
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... panels mounted on powder-coated steel ... free-standing modular cleanroom that meets ... Optional ceiling HEPA filter/fan units, ... to customer requirements. Negative-pressure ventilation, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: